

May 28, 2025

To All Persons Concerned

Name of Company Listed: Kyocera Corporation
Name of Representative: Hideo Tanimoto, Director and President
(Code number: 6971, TSE Prime Market)
Contact Person: Hiroaki Chida
Managing Executive Officer,
Executive General Manager of Headquarters
(Tel: +81-75-604-3500)

**Notice Regarding the Split of the Company's Medical Business
through the Company Split (Simplified Absorption-type Company Split)**

Kyocera Corporation (the “Company”) hereby announces that at the Board of Directors meeting held today, the Company resolved that it shall have its medical business (the “Target Business”) succeeded to Kyocera Medical Corporation (“Kyocera Medical”), a newly established wholly owned subsidiary of the Company, by way of an absorption-type company split (the “Absorption-type Company Split”) effective as of October 1, 2025 (“the Transactions”).

Since the Absorption-type Company Split falls under a simplified absorption-type company split for the Company, the disclosed items and description thereof are partially omitted.

1. Purpose of the Transactions

Kyocera Group currently develops, manufactures and sells artificial joints and dental implants, etc. in the medical business of the Core Components Business.

In recent years, the medical device industry has been facing even higher international requirements for safety and quality, and a specialized experience, knowledge and skills has become essential to accurately meet these requirements.

Kyocera Medical, as a company specialized in the medical field, will accelerate business growth by speeding up responses to diversifying needs of the market, while at the same time, establish a system that can promptly respond to the amendment to the Japan’s PMD Act* and International Standards (ISO) for medical devices.

Kyocera Group will continue to contribute to the improvement of patients' quality of life and the development of medical care in the global medical market, which has high growth potential.

* Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Act No. 145 of 1960)

2. Summary of the Transactions

(1) Schedule of the Transactions

Board of Directors resolution date : May 28, 2025

Execution date of Absorption-type Company Split Agreement

: May 28, 2025

Effective date of the Absorption-type Company Split : October 1, 2025 (tentative)

Note: As this process falls under the simplified absorption-type company split under Article 784, Paragraph 2 of the Companies Act, and the short-form absorption-type company split under Article 796, Paragraph 1 of the Companies Act for Kyocera Medical, the implementation thereof shall not be subject to resolution at the shareholders' meetings for both of the Company and Kyocera Medical.

(2) Method of the Absorption-type Company Split

The Company will be the splitting company and Kyocera Medical will be the succeeding company in the Absorption-type Company Split.

(3) Details of Allotment related to the Absorption-type Company Split

Kyocera Medical will issue one share of its common stock following the Absorption-type Company Split and allot it to the Company.

(4) Handling of Share Acquisition Rights and Bonds with Share Acquisition Rights in Connection with the Absorption-type Company Split

Not applicable.

(5) Increase or Decrease in Capital Due to the Absorption-type Company Split

There will be no increase or decrease in the capital of the Company as a result of the Absorption-type Company Split.

(6) Rights and Obligations to be Succeeded to by Kyocera Medical

As a result of the Absorption-type Company Split, Kyocera Medical will succeed the assets, liabilities and other rights and obligations relating to the Target Business as separately provided for in the Absorption-type Company Split agreement as of the effective date of the Absorption-type Company Split.

(7) Prospect for the Fulfillment of Obligations

The Company has determined that there will be no issue in the fulfillment of obligations to be borne by Kyocera Medical after the effective date of the Absorption-type Company Split.

3. Overview of the Companies Involved in the Absorption-type Company Split

	Company Splitting in the Absorption-type Company Split		Company Succeeding in the Absorption-Type Split
(1) Name	Kyocera Corporation		Kyocera Medical Corporation
(2) Location	6 Takeda Tobadono-cho, Fushimi-ku, Kyoto		6 Takeda Tobadono-cho, Fushimi-ku, Kyoto
(3) Title and Name of Representative	Hideo Tanimoto, President and Representative Director		Hidefumi Takemoto, President and Representative Director
(4) Description of Business	Core Components Business, Electronic Components Business, Solutions Business, etc.		Development, manufacturing and sales of artificial joints and dental implants, etc.
(5) Amount of Capital	JPY 115,703 million		JPY 1
(6) Date of Establishment	April 1, 1959		May 23, 2025
(7) Number of Issued and Outstanding Shares	1,510,474,320		1
(8) Fiscal Year-end	March 31		March 31
(9) Major Shareholders and Shareholding Ratio	The Master Trust Bank of Japan, Ltd. (Trust Account)	21.96%	The Company: 100%
	Custody Bank of Japan, Ltd. (Trust Account)	8.86%	
	The Bank of Kyoto, Ltd.	4.10%	
	STATE STREET BANK AND TRUST COMPANY 505001	3.82%	
	Inamori Foundation	2.66%	
	STATE STREET BANK WEST CLIENT - TREATY 505234	1.92%	

	Stock Purchase Plan for Kyocera Group Employees	1.72%	
	MUFG Bank, Ltd.	1.31%	
	HSBC HONG KONG - TREASURY SERVICES A/C ASIAN EQUITIES DERIVATIVES	1.26%	
	The Dai-ichi Life Insurance Company, Ltd.	1.19%	
(10) Consolidated Operating Results and Consolidated Financial Position for the Previous Fiscal Year (Ended March 31, 2025)			
Equity attributable to owners of the parent	JPY 3,217,788 million	—	
Total assets	JPY 4,511,307 million	—	
Equity per share attributable to owners of the parent (JPY)	JPY 2,284.15	—	
Sales revenue	JPY 2,014,454 million	—	
Operating Profit	JPY 27,299 million	—	
Profit before income taxes	JPY 63,631 million	—	
Profit attributable to owners of the parent	JPY 24,097 million	—	
Earnings per share attributable to owners of the parent - Basic (JPY)	JPY 17.11	—	

Note: Information regarding the splitting company in the Absorption-Type Company Split is as of March 31, 2025. The succeeding company in the Absorption-Type Split was established on May 23, 2025, and therefore, there are no operating results of the succeeding company for the previous fiscal year.

4. Outline of the Business Subject to the Absorption-Type Company Split

(1) Description of Business

Development, manufacturing and sales of artificial joints and dental implants, etc.

(2) Consolidated Operating Results of the Business to be Split (the Year ended March 31, 2025)

Sales revenue: JPY 20,450 million

(3) Items of Assets and Liabilities and Book Value Subject to the Absorption-Type Company Split

Current assets: JPY 29,213 million

Non-current assets: JPY 3,402 million

Current liabilities: JPY 1,056 million

Non-current liabilities: JPY 38 million

Note: The above amounts are calculated based on the balance sheet as of March 31, 2025, and therefore, the actual amounts to be succeeded will be subject to the adjustment reflecting the changes in the above amounts up to the effective date.

5. Situation After the Absorption-type Company Split

There will be no changes in the name, location, title and name of the representative, description of business (except for the Target Business), amount of capital or fiscal year-end of the Company as a result of the Absorption-type Company Split.

Kyocera Medical schedules to increase its capital to JPY 50 million as from October 1, 2025.

6. Outlook

The impact of the Transactions on the Company's consolidated financial results will be immaterial, because parties to the Transactions are the Company and the Company's wholly owned subsidiary.

Cautionary Statements with respect to Forward-Looking Statements

Certain of the statements made in this document are forward-looking statements, which are based on our current assumptions and beliefs in light of the information currently available to us. These forward-looking statements involve known and unknown risks, uncertainties and other factors. Such risks, uncertainties and other factors include, but are not limited to the following:

- (1) General conditions in the Japanese or global economy;
- (2) Unexpected changes in economic, political and legal conditions in countries where we operate or export;
- (3) The effect of foreign exchange fluctuations on our results of operations;
- (4) Intense competitive pressures to which our products are subject;
- (5) Fluctuations in the price and ability of suppliers to provide the required quantity of raw materials for use in our production activities;
- (6) Manufacturing delays or defects resulting from outsourcing or internal manufacturing processes;
- (7) The possibility that future initiatives and in-process research and development may not produce the desired results;
- (8) Companies or assets acquired by us not produce the returns or benefits, or bring in business opportunities;
- (9) Inability to secure skilled employees;
- (10) Damages on our information security systems from cyberattacks, etc. and significant costs in order to recover and maintain the systems;
- (11) Insufficient protection of our trade secrets and intellectual property rights including patents;
- (12) Expenses associated with licenses we require to continue to manufacture and sell products;
- (13) Unintentional conflict with laws and regulations or newly enacted laws and regulations;
- (14) Environmental liability and compliance obligations by tightening of environmental laws and regulations;
- (15) Inability to respond to global climate change problems or delay in such response, which may lead to increased costs and negatively impact our corporate brands;
- (16) Our market or supply chains being affected by plague, infectious diseases, terrorism, wars or similar events;
- (17) Earthquakes and other natural disasters affecting our headquarters and major facilities as well as our suppliers and customers;
- (18) Credit risk on trade receivables;
- (19) Fluctuations in the value of financial instruments held by us;
- (20) Impairment losses on property, plant and equipment, goodwill and intangible assets;
- (21) Uncertainty over income tax and deferred tax assets; and
- (22) Changes in accounting standards.

Due to such risks, uncertainties and other factors, our actual results, performance, achievements or financial condition may be substantially different from any future results, performance, achievements or financial condition expressed or implied by these forward-looking statements. We undertake no obligation to publicly update any forward-looking statements included in this document.